Novamind Ventures' new CMO has led over 100 clinical trials and currently serves as a Coordinating Investigator for MAPS.
Entheon Biomedical
Company Brief
Entheon Biomedical seeks to research, develop, patent, and distribute psilocybin and DMT based medicines and treatments for those suffering from substance-abuse disorders.This under-serviced market was valued at US$ 13.22 Billion in 2016, and is expected to grow to US$ 27.91 Billion by 2025.
Highlights
Related Articles
Champignon to Begin Offering Esketamine Treatment for Adults With Major Depressive Disorder at the Canadian Rapid Treatment Centre of Excellence
Champignon Brands advises that the BCSC has revoked its original cease trade order (June 19, 2020), but a replacement order remains in effect.
TSI EDITOR |
2020-08-27
Psychedelic Drugs Go Mainstream
As the Renaissance for psychedelic drugs progresses, we see these substances acquiring mainstream status in various ways.
TSI EDITOR |
2020-08-27
Mydecine Innovations Group Announces Extended Lock-Up Arrangement
Certain large Mydecine shareholders have entered into a voluntary lock-up, covering 52,908,420 common shares.
TSI EDITOR |
2020-08-26
MindMed Announces First-Ever Clinical Trial Combining MDMA and LSD
MindMed is utilizing MDMA with LSD, to endeavour to reduce side effects of LSD-assisted therapy.
TSI EDITOR |
2020-08-25
Field Trip Psychedelics Inc. Announces Closing of $11.0 million Financing, Entry into Amalgamation Agreement with Newton Energy Corporation
Field Trip Psychedelics completes its qualifying transaction and definitive agreement with RTO partner.
TSI EDITOR |
2020-08-24
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now